Literature DB >> 31638510

Laparoendoscopic Single-Site (LESS) versus Robotic "Redo" Hiatal Hernia Repair with Fundoplication: Which Approach Is Better?

Andres Giovannetti, Danielle Craigg, Miguel Castro, Sharona Ross, Iswanto Sucandy, Alexander Rosemurgy.   

Abstract

Only a small percentage of patients fail laparoscopic fundoplications undertaken for gastroesophageal reflux disease. But because many laparoscopic fundoplications have been undertaken, surgeons frequently encounter patients in need of "redo" operations. This study was undertaken to evaluate the robotic approach versus laparoendoscopic single-site (LESS) approach for redo fundoplications. With an Institutional Review Board approval, 64 patients undergoing LESS (n = 32) or robotic (n = 32) redo antireflux operations were prospectively followed up. Data are presented as median (mean + SD). For LESS versus robotic redo operations, the operative duration was 145 (143 ± 33.5) versus 196 (208 ± 76.7) minutes (P < 0.01), estimated blood loss was 50 (80 ± 92.1) versus 20 (43 ± 57.1) mL (P = 0.07), and length of stay was 1 (3 ± 5.4) versus 1 (2 ± 1.9) day (P = 0.57); 1 LESS operation was converted to "open." Operative duration was longer for men (P = 0.01). Postoperative complications were not more frequent after Nissen (n = 36) or Toupet (n = 28) fundoplication, regardless of the approach. When matched by BMI, operative duration was prolonged by a large Type I to IV hiatal hernia (P = 0.01). Symptoms improved dramatically and were similar with both approaches, and patient satisfaction was high. Robotic redo antireflux operations take longer than LESS operations. LESS and robotic redo antireflux operations are both safe and offer significant and similar amelioration of symptoms after failed fundoplications.

Entities:  

Mesh:

Year:  2019        PMID: 31638510

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  1 in total

1.  Robotic Complex Fundoplication in Patients at High-Risk to Fail.

Authors:  Kenneth Luberice; Sharona Ross; Kaitlyn Crespo; Christina De La Cruz; John-Kevin Dolce; Iswanto Sucandy; Alexander S Rosemurgy
Journal:  JSLS       Date:  2021 Apr-Jun       Impact factor: 2.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.